Walser T, Cui X, Yanagawa J, Lee JM, Heinrich E, Lee G, Sharma S, Dubinett SM: Smoking and lung cancer. The role of inflammation. Proc Am Thorac Soc. 2008, 5: 811-815.
Soussi T: p53 antibodies in the sera of patients with various types of cancer: a review. Cancer Res. 2000, 60: 1777-1788.
Hill KA, Sommer SS: p53 as a mutagen test in breast cancer. Environ Mol Mutagen. 2002, 39: 216-227.
Dowing SR, Russell PJ, Jackson P: Alterations in p53 are common in early stage prostate cancer. Can J Urol. 2003, 10: 1924-1933.
Gao RJ, Bao HZ, Yang Q, Cong Q, Song JN, Wang L: The presence of serum anti-p53 antibodies from patients with invasive ductal carcinoma of breast: correlation to other clinical and biological parameters. Breast Cancer Res Treat. 2005, 93: 111-115.
Cawley HM, Meltzer SJ, De Benedetti VM, Hollstein MC, Muehlbauer KR, Liang L, Bennett WP, Souza RF, Greenwald BD, Cottrell J, Salabes A, Bartsch H, Trivers GE: Anti-p53 antibodies in patients with Barrett’s esophagus or esophageal carcinoma can predate cancer diagnosis. Gastroenterology. 1998, 115: 19-27.
Yoshizawa S, Matsuoka K, Inoue N, Takaishi H, Ogata H, Iwao Y, Mukai M, Fujita T, Kawakami Y, Hibi T: Clinical significance of serum p53 antibodies in patients with ulcerative colitis and its carcinogenesis. Inflamm Bowel Dis. 2007, 13: 865-873.
Li Y, Karjalainen A, Koskinen H, Hemminki K, Vainio H, Shnaidman M, Ying Z, Pukkala E, Brandt-Rauf PW: p53 autoantibodies predict subsequent development of cancer. Int J Cancer. 2005, 114: 157-160.
Martin B, Verdebout JM, Mascaux C, Paesmans M, Rouas G, Verhest A, Ninane V, Sculier JP: Expression of p53 in preneoplastic and early neoplastic bronchial lesions. Oncol Rep. 2002, 9: 223-229.
Lubin R, Zalcman G, Bouchet L, Trédanel J, Legros Y, Cazals D, Hirsch A, Soussi T: Serum p53 antibodies as early markers of lung cancer. Nat Med. 1995, 1: 701-702.
Trivers GE, De Benedetti VM, Cawley HL, Caron G, Harrington AM, Bennett WP, Jett JR, Colby TV, Tazelaar H, Pairolero P, Miller RD, Harris CC: Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. Clin Cancer Res. 1996, 2: 1767-1775.
Youlden DR, Cramb SM, Baade PD: The international epidemiology of lung cancer: geographical distribution and secular trends. J Thorac Oncol. 2008, 3: 819-831.
Hecht SS: Progress and challenges in selected areas of tobacco carcinogenesis. Chem Res Toxicol. 2008, 21: 160-171.
Wasswa-Kintu S, Gan WQ, Man SF, Pare PD, Sin DD: Relationship between reduced forced expiratory volume in one second and the risk of lung cancer: a systematic review and meta-analysis. Thorax. 2005, 60: 570-575.
Loganathan RS, Stover DE, Shi W, Venkatraman E: Prevalence of COPD in women compared to men around the time of diagnosis of primary lung cancer. Chest. 2006, 129: 1305-1312.
Papi A, Casoni G, Caramori G, Guzzinati I, Boschetto P, Ravenna F, Calia N, Petruzzelli S, Corbetta L, Cavallesco G, Forini E, Saetta M, Ciaccia A, Fabbri LM: COPD increases the risk of squamous histological subtype in smokers who develop non-small cell lung carcinoma. Thorax. 2004, 59: 679-681.
Engels EA: Inflammation in the development of lung cancer: epidemiological evidence. Expert Rev Anticancer Ther. 2008, 8: 605-615.
Brower V: Feeding the flame: new research adds to role of inflammation in cancer development. J Natl Cancer Inst. 2005, 97: 251-253.
Komarova EA, Krivokrysenko V, Wang K, Neznanov N, Chernov MV, Komarov PG, Brennan ML, Golovkina TV, Rokhlin OW, Kuprash DV, Nedospasov SA, Hazen SL, Feinstein E, Gudkov AV: p53 is a suppressor of inflammatory response in mice. FASEB J. 2005, 19: 1030-1032.
Subbaramaiah K, Altorki N, Chung WJ, Mestre JR, Sampat A, Dannenberg AJ: Inhibition of cyclooxygenase-2 gene expression by p53. J Biol Chem. 1999, 274: 10911-10915.
Richardson CM, Sharma RA, Cox G, O'Byrne KJ: Epidermal growth factor receptors and cyclooxygenase-2 in the pathogenesis of non-small cell lung cancer: potential targets for chemoprevention and systemic therapy. Lung Cancer. 2003, 39: 1-13.
Wistuba II, Mao L, Gazdar AF: Smoking molecular damage in bronchial epithelium. Oncogene. 2002, 21: 7298-7306.
Purdue MP, Gold L, Järvholm B, Alavanja MC, Ward MH, Vermeulen R: Impaired lung function and lung cancer incidence in a cohort of Swedish construction workers. Thorax. 2007, 62: 51-56.
Cioffi M, Riegler G, Vietri MT, Pilla P, Caserta L, Carratù R, Sica V, Molinari AM: Serum p53 antibodies in patients affected with ulcerative colitis. Inflamm Bowel Dis. 2004, 10: 606-611.
Agaylan A, Binder D, Sauer M, Neuweiler H, Meyer O, Kiesewetter H, Salama A: A highly sensitive particle agglutination assay for the detection of p53 autoantibodies in patients with lung cancer. Cancer. 2007, 110: 2502-2506.
Park Y, Kim Y, Lee J-H, Lee EY, Kim H-S: Usefulness of serum anti-p53 antibody assay for lung cancer diagnosis. Arch Pathol Lab Med. 2011, 135: 1570-1575.
R Development Core Team: 3-900051-07-0. R: a language and environment for statistical computing. 2004, Vienna, Austria: The R Foundation for Statistical Computing, http://www.R-project.org/,
Husgafvel-Pursiainen K, Kannio A: Cigarette smoking and p53 mutations in lung cancer and bladder cancer. Environ Health Perspect. 1996, 104: 553-556.
Li Y, Brandt-Rauf PW, Carney WP, Tenney DY, Ford JG: Circulating anti-p53 antibodies in lung cancer and relationship to histology and smoking. Biomarkers. 1999, 4: 381-390.
Pascual RM, Peters SP: Airway remodelling contributes to the progressive loss of lung function in asthma: an overview. J Allergy Clin Immunol. 2005, 116: 477-486.
Moss SF, Blaser MJ: Mechanisms of disease: inflammation and the origins of cancer. Nat Clin Pract Oncol. 2005, 2: 90-97.
Mulcahy HE, Lyautey J, Lederrey C, Chen X, Anker P, Alstead EM, Ballinger A, Farthing MJ, Stroun M: A prospective study of K-ras mutations in the plasma of pancreatic cancer patients. Clin Cancer Res. 1998, 4: 271-275.
Partanen R, Hemminki K, Koskinen H, Luo JC, Carney WP, Brand-Rauf PW: The detection of increased amounts of the extracellular domain of the epidermal growth factor receptor in serum during carcinogenesis in asbestosis patients. J Occup Med. 1994, 36: 1324-1328.
Cockayne DA, Cheng DT, Waschki B, Sridhar S, Ravindran P, Hilton H, Kourteva G, Bitter H, Pillai SG, Visvanathan S, Muller K-C, Holz O, Magnussen H, Watz H, Fine JS: Systemic biomarkers of neutrophilic inflammation, tissue injury and repair in COPD patients with differing levels of disease severity. PLoS ONE. 2012, 7: e38629-10.1371.